Encapsulation of rhBMP-2 as a Strategy for Dose Shielding Whilst Preserving Structural Integrity, Bioactivity, and Osteogenic Potential

Recombinant human bone morphogenetic protein-2 (rhBMP-2) is widely used to promote bone regeneration. However, conventional surface-attached delivery on absorbable collagen sponges causes a rapid burst release, excessive inflammation, and suboptimal healing. To overcome these limitations, we developed a thermally controlled Poly(DL-lactide-co-glycolide) (PDLLGA) encapsulation system, designed to stabilize rhBMP-2 and enable controlled release. rhBMP-2 was incorporated in PDLLGA pellets using the hot-melt extrusion of a lyophilized mixture containing poloxamer 407 and hydroxypropyl-β-cyclodextrin, and terminal sterilization (X-ray irradiation). The released rhBMP-2 maintained its molecular integrity after sterilization and remained stable for up to 732 days in storage, as confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and capillary electrophoresis (CE). Further, high-affinity binding between released rhBMP-2 and BMPR-IA was confirmed by bio-layer interferometry (BLI), and the released protein induced a robust in vitro ALP response, confirming preserved osteogenic activity. Our encapsulation approach for rhBMP-2 using PDLLGA, including the combination product with β-TCP (LDGraft; Locate Bio, Nottingham, UK), provides a stable and bioactive rhBMP-2 delivery strategy with inherent dose-shielding properties, supporting safe, controlled, and effective bone regeneration therapies.